Steps solidifying a role for SEPT9 in breast cancer suggest that greater strides are needed

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Stanbery, Laura ^a   Petty, Elizabeth M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; SEPT9 PROTEIN; SEPTIN; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CARCINOGENESIS; CELL FUNCTION; CELL IMMORTALIZATION; CELLULAR DISTRIBUTION; CYTOPLASM; EDITORIAL; HUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; FEMALE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NOTE;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; HUMANS; SEPTINS;

EID: 84855614381     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3056     Document Type: Editorial

References (24)

1. Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, Fazzari MJ, Verdier-Pinard P, Montagna C. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res 2011, 13:R76. 10.1186/bcr2924, 3236340, 21831286.
2. Hartwell LH. Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis. Exp Cell Res 1971, 69:265-276. 10.1016/0014-4827(71)90223-0, 4950437.
3. Russell SEH, Hall PA. Septin genomics: a road less travelled. Biol Chem 2011, 392:763-767. 10.1515/BC.2011.079, 21809895.
4. Peterson EA, Petty EM. Conquering the complex world of human septins: implications for health and disease. Clin Genet 2010, 77:511-524. 10.1111/j.1399-0004.2010.01392.x, 20236126.
5. Connolly D, Abdesselam I, Verdier-Pinard P, Montagna C. Septin roles in tumorigenesis. Biol Chem 2011, 392:725-738. 10.1515/BC.2011.073, 21740328.
6. Roeseler S, Sandrock K, Bartsch I, Zieger B. Septins, a novel group of GTP-binding proteins: relevance in hemostasis, neuropathology and oncogenesis. Klin Padiatr 2009, 221:150-155. 10.1055/s-0029-1220706, 19437362.
7. Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci USA 1999, 96:6428-6433. 10.1073/pnas.96.11.6428, 26898, 10339604.
8. Kalikin LM, Sims HL, Petty EM. Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors. Genomics 2000, 63:165-172. 10.1006/geno.1999.6077, 10673329.
9. Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res 2000, 60:4729-4734.
10. Sandrock K, Bartsch I, Busse A, Busse E, Zieger B. Characterization of human septin interactions. Biol Chem 2011, 392:751-761. 10.1515/BC.2011.081, 21767235.
11. Peterson EA, Kalikin LM, Steels JD, Estey MP, Trimble WS, Petty EM. Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin. Mamm Genome 2007, 18:796-807. 10.1007/s00335-007-9065-x, 17922164.
12. Gonzalez ME, Peterson EA, Privette LM, Loff reda-Wren JL, Kalikin LM, Petty EM. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res 2007, 67:8554-8564. 10.1158/0008-5472.CAN-07-1474, 17875694.
13. Stanbery L, D'Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, Wolf GT, Worden FP, Cordell KG, Petty EM. High SEPT9_v1 expression is associated with poor clinical outcomes in head and neck squamous cell carcinoma. Transl Oncol 2010, 3:239-245. 2915415, 20689765.
14. Amir S, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. Cancer Res 2006, 66:856-866. 10.1158/0008-5472.CAN-05-2738, 16424018.
15. Bennett KL, Romigh T, Eng C. Disruption of transforming growth factorbeta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. Cancer Res 2009, 69:9301-9305. 10.1158/0008-5472.CAN-09-3073, 19934318.
16. Toth K, Galamb O, Spisak S, Wichmann B, Sipos F, Valcz G, Leiszter K, Molnar B, Tulassay Z. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol Oncol Res 2011, 17:503-509. 10.1007/s12253-010-9338-7, 21267688.
17. Hannibal MC, Ruzzo EK, Miller LR, Betz B, Buchan JG, Knutzen DM, Barnett K, Landsverk ML, Brice A, LeGuern E, Bedford HM, Worrall BB, Lovitt S, Appel SH, Andermann E, Bird TD, Chance PF. SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy. Neurology 2009, 72:1755-1759. 10.1212/WNL.0b013e3181a609e3, 2683739, 19451530.
18. Amir S, Golan M, Mabjeesh NJ. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res 2010, 8:643-652. 10.1158/1541-7786.MCR-09-0497, 20407014.
19. Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal 2009, 21:477-487. 10.1016/j.cellsig.2008.11.007, 2811713, 19071215.
20. Surka MC, Tsang CW, Trimble WS. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. Mol Biol Cell 2002, 13:3532-3545. 10.1091/mbc.E02-01-0042, 129964, 12388755.
21. Estey MP, Di Ciano-Oliveira C, Froese CD, Bejide MT, Trimble WS. Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. J Cell Biol 2010, 191:741-749. 10.1083/jcb.201006031, 2983063, 21059847.
22. Peterson EA, Stanbery L, Li C, Kocak H, Makarova O, Petty EM. SEPT9_i1 and genomic instability: Mechanistic insights and relevance to tumorigenesis. Genes Chromosomes Cancer 2011, 50:940-949. 10.1002/gcc.20916, 21910160.
23. Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Repert T, Hissong B, Weaver Z, Reid T. The Septin 9 (MSF) gene is ampliofied and overexdpressed in mouse mammary gland ademocarcinomas and human breast cancer cell lines. Cancer Res 2003, 63:2179-2187.
24. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, Fleshner PR, Oubre BM, Day R, Sledziewski AZ, Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009, 55:1337-1346. 10.1373/clinchem.2008.115808, 19406918.